Teladoc shareholders worried about post-pandemic blues, but it's Amwell that's seeing the slowdown

Telemedicine pioneer Teladoc Health had an incredible 2020. The pandemic turned the small but growing remote virtual care niche of the healthcare industry into a basic staple. Amwell on the other hand -- not so much. Its fourth-quarter 2020 results were decent enough, but the outlook for the new year implies the health technologist's expansion will slow to a snail's pace.